Metroplex Clinical Research Center Plans 2nd Phase I Expansion

Metroplex Clinical Research Center

(MCRC), a multiphase clinical research site in Dallas, recently announced plans to expand its Phase I unit from 5,000 to 7,500 square feet in response to rising demand for early phase studies. Last year, MCRC and Rheumatology Associates announced the opening of their 22,500-square-foot complex featuring rheumatology services and Phase I-IV research services under one roof. This pairing at 8144 Walnut Hill Lane, Suites 800 and 810, presents opportunities for patients with rheumatic disease.

"So many drugs that were intravenous for years are now coming into research studies with subcutaneous formulations. Oral small molecules that target the inflammatory pathway are being developed as well. In response to the need for sites that have Phase I capacities, we expanded our Phase I unit in 2009 and will be doubling our capacity to 12 beds, expanding our services to include healthy volunteer studies," said Sara Monday, MCRC's Chief Operating Officer.

The MCRC has experience with first human dose; first dose in patients with disease; maximum tolerated dose in healthy patients; biologicals, including vaccine and monoclonal antibodies; clinical pharmacology (PK/PD) Phase Ia, Ib; drug interaction; and early efficacy studies (Phase IIa). Since 1984, MCRC has completed more than 1,000 Phase I-IV clinical studies in several therapeutic areas.

MCRC's Phase I unit currently features critical care staff certified in Advanced Cardiac Life Support (ACLS), 24-hour physician coverage, recreation and lounge facilities, and spacious bedrooms with wireless Internet, television and personal DVD players.

Construction crews will begin work within two weeks toward an expected completion date of April 1, 2011.